Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 21, 2014
Pharmacy Choice - News - Generic Drugs - April 21, 2014

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 68     Next >>     Go To Page:

4/19/14 - Particle Sciences and Actavis Enter into Joint Development Agreement
By a News Reporter-Staff News Editor at Marketing Weekly News Particle Sciences, a drug delivery Contract Development and Manufacturing Organization, announced that they have entered into an exclusive agreement with Actavis plc, a leading specialty pharmaceutical company, to develop an unnamed complex generic product. Actavis will have responsibi
4/19/14 - Some generic drugs have had eye-popping price spikes [Fort Worth Star-Telegram :: ]
April 19 Pharmacist Larry Cowan can flip through his records and spot the generic drugs that have taken big price jumps in the past year or so. "Now the price is close to 10 times that," said Cowan, owner of Glenview Professional Pharmacy in Richland Hills. While the FDA in the past month removed doxycyline from its shortage list, it still costs
4/19/14 - Teva Announces Supreme Court Denial of Request for Interim Relief to Stay Court of Appeals Ruling for COPAXONE Patent Due to the Potential for the Company to Recover Patent Infringement Damages
Teva Pharmaceutical Industries Ltd. announced that while the Chief Justice of the United States found that Teva had demonstrated a fair prospect of success on the merits in its appeal of a decision from the United States Court of Appeals for the Federal Circuit that invalidated the claim of U.S. Teva will continue pursuing its appeal in the S
4/18/14 - Actavis Confirms Favorable Ruling in Generic Lialda Patent Suit
By a News Reporter-Staff News Editor at Health& Medicine Week Actavis plc confirmed that the United States Court of Appeals for the Federal Circuit has reversed a lower court ruling that Actavis' generic version of Shire's Lialda infringes United States Patent No. 6,773,720. Actavis' Abbreviated New Drug Application for its generic version of Lia
4/18/14 - Court declines to block drug ruling in patent case
WASHINGTON The Supreme Court has declined to temporarily block a lower court ruling that opens the world's best-selling multiple sclerosis drug to competition from generic rivals. Teva claims the U.S. Court of Appeals for the Federal Circuit wrongly overturned five of its patents for the drug. That ruling allows rivals Mylan Inc., Momenta Pharma
4/18/14 - Lannett Gets FDA Approval for Diazepam Oral Solution (Concentrate), 5 mg/mL [Health & Beauty Close - Up]
Lannett Company, Inc. said that it has received approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application for Diazepam Oral Solution, 5 mg/ mL, a Schedule C-IV controlled drug. "We believe our ANDA for Diazepam Oral Solution, 5 mg/mL was the first bioequivalent Diazepam Oral Solution product approved by the FDA,"
4/18/14 - Perrigo Announces Launch Of Authorized Generic Version Of Taclonex Ointment Calcipotriene 0.005% / Betamethasone Dipropionate 0.064%
By a News Reporter-Staff News Editor at Health& Medicine Week Perrigo Company plc announced that it has initiated market launch and made its first shipments of the authorized generic version of LEO Pharma A/S' Taclonex Ointment. >From its beginnings as a packager of generic home remedies in 1887, Perrigo Company plc, headquartered in Ireland,
4/18/14 - Teva Introduces Generic Lunesta Tablets in the United States [Professional Services Close - Up]
Teva Pharmaceutical Industries announced the launch of the generic equivalent to Lunesta, 1, 2 and 3 mg, in the United States. According to a release, Lunesta Tablets, marketed by Sunovion Pharmaceuticals, had annual sales of approximately $852 million in the United States, according to IMS data as of December 2013. Teva Pharmaceutical Industries i
4/18/14 - US top court denies Israel's Teva Pharmaceuticals stay in Copaxone patent fight [Jerusalem Post (Israel)]
WASHINGTON- US Supreme Court Chief Justice John Roberts on Friday denied a request by Teva Pharmaceutical Industries Ltd to stay a lower-court ruling in a patent case that favored the developers of generic versions of Teva's top-selling multiple sclerosis drug.. Teva had sought to prevent the lower-court ruling from going into effect while the Supr
4/17/14 - Actavis Announces Agreement Related to Generess FE Patent Challenge Litigation [Global Data Point]
Under the terms of the agreement, Actavis will grant Mylan a license to market its generic version of Generess FE under its pending Abbreviated New Drug Application beginning on April 1, 2015.&# x0D;. Alternatively, Mylan will be permitted to launch an authorized generic version of Actavis' product beginning on October 1, 2015. Actavis remains i
4/17/14 - Actavis to Acquire Four Products from Akorn
Actavis plc, a leading global specialty pharmaceutical company, today announced that it has entered into agreements with Akorn, Inc. and Hi-Tech Pharmacal Co. Inc. to purchase four currently marketed products and one product under development for cash consideration. Actavis plc is a global, integrated specialty pharmaceutical company focused on...
4/17/14 - Actavis to Acquire Four Products from Akorn; Terms Undisclosed
Actavis plc, a leading global specialty pharmaceutical company, today announced that it has entered into agreements with Akorn, Inc. and Hi-Tech Pharmacal Co. Inc. to purchase four currently marketed products and one product under development for cash consideration. Actavis plc is a global, integrated specialty pharmaceutical company focused on...
4/17/14 - Akorn Completes Acquisition of Hi-Tech Pharmacal
Akorn, Inc., a niche pharmaceutical company, announced today that it has completed its previously announced acquisition of Hi-Tech Pharmacal Co., Inc. for $640 million in cash. The combination of Akorn and Hi-Tech will transform the Company into a larger, more diversified generic player. We are excited to announce that we have completed the acqu
4/17/14 - Biosimilars Market by Product & Application - Global Forecast to 2018
Dublin- Research and Markets has announced the addition of the "Biosimilars Market by Product& Application- Global Forecast to 2018" report to their offering. The global market is segmented on the basis of products, applications, and services. The global market will be worth $2.0 billion by 2018, growing at a CAGR of 20.1% during the forecast perio
4/17/14 - BRIEF: Teva settles with Pfizer on arthritis treatment [Globes, Tel Aviv, Israel :: ]
April 17 Teva Pharmaceutical Industries Ltd. has settled with Pfizer Inc. on Teva's generic version of Pfizer's arthritis drug Celebrex capsules in the US. Under the terms of the settlement, Teva may launch its generic versions in December 2014, or earlier under certain circumstances. Teva has received Tentative Approval from the US Food and Drug
4/17/14 - Generic Viagra worth Rs90k seized [DNA : Daily News & Analysis (India)]
The Rajasthan Drug Control Organisation on Wednesday seized several samples of masculinity enhancing drugs which were being sold as' Ayurvedic' medicines but were a blend of allopathic medicines. The department officials took drug samples from Hardik Remedies Pharma Plaza, Film Colony and seized stock worth Rs90, 000. The Drug Control Organisation.
4/17/14 - JCM Updates on Azithromycin API Export
Tianyin Pharmaceutical Inc., a pharmaceutical company that specializes in the development and sale of patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics, and active pharmaceutical ingredients, updated regarding the recent progress of the Jiangchuan Macrolide Facility. JCM has developed a new line of...
4/17/14 - Teva recalls anti-depressant - report [Globes, Tel Aviv, Israel :: ]
Teva began marketing its generic version of the drug in the fourth quarter of 2012.. Teva produces generic Cymbalta at its plant in Jerusalem. "The safety and efficacy of our medicines is one of Teva's top priorities.
4/17/14 - Teva Settles Patent Litigation with Pfizer on Celebrex; Has Received Tenative FDA Approval for All Strengths; May Start Generic Versions in December
Teva Pharmaceutical Industries Ltd. announced today that its subsidiary Teva Pharmaceuticals USA, Inc. has entered into a settlement with Pfizer related to Teva's generic version of Celebrex 50, 100, 200 and 400 mg capsules in the United States. Under the terms of the settlement, Teva may launch its generic versions in December, 2014, or earlier
4/17/14 - Teva Settles Patent Litigation with Pfizer on Celebrex
Under the terms of the settlement, Teva may launch its generic versions in December, 2014, or earlier under certain circumstances. Teva has received tentative approval from the U.S. Food and Drug Administration for all strengths and believes that it is first-to-file on at least the 100, 200 and 400 mg capsules. Headquartered in Israel, Teva is the
4/17/14 - ViiV Healthcare announces new initiatives to improve access to dolutegravir: licence to the Medicines Patent Pool
By a News Reporter-Staff News Editor at Politics& Government Week ViiV Healthcare announced new collaborations with the goal of increasing access to its HIV medicine, dolutegravir, just two months after its approval by the European Medicines Agency and eight months after approval by the US Food and Drug Administration. Through an agreement with t
4/16/14 - Actavis Acquires Silom Medical Company
By a News Reporter-Staff News Editor at Biotech Week Actavis plc, a leading global specialty pharmaceutical company announced that it has acquired Silom Medical Company, a privately held generic pharmaceutical company focused on developing and marketing therapies in Thailand, for approximately $100 million in cash. "Silom Medical's diverse produ
4/16/14 - AMRI Finalizes Acquisition of Cedarburg Pharmaceuticals [Professional Services Close - Up]
AMRI announced that it has completed the previously announced acquisition of Cedarburg Pharmaceuticals, Inc.. According to a release, Cedarburg, whose capabilities both augment and complement those of AMRI, is a contract developer and manufacturer of technically complex active pharmaceutical ingredients for both generic and branded customers.
4/16/14 - Boston Scientific Reports FDA Approval for Heart Failure Devices; Teva Unveils Generic Lunesta Tablets in US
Below is a look at some of the headlines for companies that made news in the healthcare sector on April 15, 2014.{ nfg} Boston Scientific Corporation has received FDA approval for its latest generation of defibrillators and heart failure devices designed to advance patient care. These newly approved devices continue the Boston Scientific history of
4/16/14 - BRIEF: Teva launches generic insomnia treatment in US [Globes, Tel Aviv, Israel :: ]
April 16 Teva Pharmaceutical Industries Ltd. has launched generic Lunesta, for the treatment of insomnia, in the US. Brand Lunesta, marketed by Sunovion Pharmaceuticals Inc., had $852 million in US sales in 2013, according to IMS. Glenmark Generics Ltd. and Mylan Inc. also obtained marketing approval for generic Lunesta.
Articles(s): 1 - 25 of 68     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Drug Therapy Management Series Part II: Psychiatric Disorders
This lesson is supported by:
RxSchool
An Overview of Complementary and Alternative Medicine
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415